MetLife Investment Advisors LLC Sells 4,777 Shares of Petmed Express Inc (PETS)

MetLife Investment Advisors LLC reduced its holdings in shares of Petmed Express Inc (NASDAQ:PETS) by 33.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,436 shares of the company’s stock after selling 4,777 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Petmed Express were worth $219,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. BlackRock Inc. increased its holdings in Petmed Express by 1.1% during the 4th quarter. BlackRock Inc. now owns 3,076,147 shares of the company’s stock valued at $71,550,000 after acquiring an additional 33,290 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in shares of Petmed Express by 47.9% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,268,358 shares of the company’s stock worth $29,502,000 after purchasing an additional 410,636 shares during the last quarter. LSV Asset Management boosted its stake in shares of Petmed Express by 624.1% during the 4th quarter. LSV Asset Management now owns 564,787 shares of the company’s stock worth $13,136,000 after purchasing an additional 486,787 shares during the last quarter. River Road Asset Management LLC acquired a new stake in shares of Petmed Express during the 4th quarter worth about $11,022,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Petmed Express by 24.4% during the 4th quarter. Bank of New York Mellon Corp now owns 434,514 shares of the company’s stock worth $10,107,000 after purchasing an additional 85,173 shares during the last quarter. Hedge funds and other institutional investors own 95.04% of the company’s stock.

Several equities research analysts have issued reports on PETS shares. BidaskClub raised shares of Petmed Express from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 22nd. Craig Hallum decreased their price target on shares of Petmed Express from $25.00 to $18.00 and set a “sell” rating on the stock in a research note on Wednesday, January 23rd. Finally, ValuEngine cut shares of Petmed Express from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Three research analysts have rated the stock with a sell rating and two have issued a hold rating to the company. Petmed Express currently has a consensus rating of “Sell” and a consensus target price of $28.00.

Petmed Express stock opened at $22.31 on Friday. Petmed Express Inc has a 12-month low of $20.25 and a 12-month high of $46.83. The stock has a market cap of $461.24 million, a price-to-earnings ratio of 11.10 and a beta of 0.51.

Petmed Express (NASDAQ:PETS) last released its quarterly earnings results on Tuesday, January 22nd. The company reported $0.38 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.48 by ($0.10). Petmed Express had a return on equity of 32.89% and a net margin of 14.43%. The firm had revenue of $60.10 million for the quarter, compared to analyst estimates of $64.22 million. During the same period in the prior year, the business earned $0.44 earnings per share. Petmed Express’s revenue for the quarter was up .0% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: This report was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/21/metlife-investment-advisors-llc-sells-4777-shares-of-petmed-express-inc-pets.html.

Petmed Express Company Profile

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Further Reading: Average Daily Trade Volume Explained

Institutional Ownership by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.